Endo Ventures, a subsidiary of Malvern-based Endo, has reached an agreement with Taiwan Liposome to commercialize its experimental osteoarthritis knee pain drug in the United States, pending regulatory approval, writes John George for the Philadelphia Business Journal. 

Under the terms of the deal with the Taiwanese company, Endo will have exclusive rights to manufacture, market, sell, and distribute the product at home. Endo made a payment of $30 million upfront to Taiwan Liposome, which will be eligible for an additional $110 million, depending on the fulfillment of development, regulatory, and manufacturing milestones. 

The drug candidate, known as TLC599, is an injectable compound that is currently in late-stage clinical testing. 

Endo’s executive vice president and president of global commercial operations, Patrick Barry, said that the experimental drug is “fully aligned” with Endo’s commitment to offering new nonsurgical treatment options to medical professionals and their patients. 

The specialty pharmaceutical company is expecting to launch TLC599 in the U.S. in 2025. 

Development of the product remains the responsibility of Taiwan Liposome, while Endo Ventures will work on obtaining regulatory approval and be responsible for the product’s commercialization in the U.S. 

Read more about Endo in the Philadelphia Business Journal.